Conversely, abrogating binding of podoplanin found on the surface of melanoma, breast cancer, lung cancer and osteosarcoma cells to C-type lectin-like receptor 2 (CLEC-2) on platelets has been shown to reduce TCIPA in vitro and VTE in mouse models13–16. This evidence concerns the gene CLEC1B and breast carcinoma.